Related Experiment Video
Updated: Jul 17, 2026
06:08
A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
Elevated serum chromogranin A concentrations in small-cell lung carcinoma
Annals of Internal Medicine
|November 1, 1986
Summary
Serum chromogranin A is a useful biomarker for small-cell lung carcinoma (SCLC). Elevated levels were significantly higher in SCLC patients compared to other lung conditions, indicating its potential for disease activity monitoring.
Area of Science:
- Oncology
- Biochemistry
Background:
- Small-cell lung carcinoma (SCLC) is an aggressive malignancy.
- Accurate biomarkers are crucial for SCLC diagnosis and monitoring disease activity.
Purpose of the Study:
- To evaluate serum chromogranin A (CgA) as a potential biomarker for SCLC.
- To compare CgA levels in SCLC patients with healthy individuals and those with other lung diseases.
Main Methods:
- Serum CgA concentrations were measured using radioimmunoassay.
- CgA levels were compared across groups: SCLC patients, healthy adults, and patients with non-small-cell lung carcinoma (NSCLC) or chronic obstructive pulmonary disease (COPD).
Main Results:
- Mean serum CgA was significantly higher in SCLC patients (815 ng/mL) than in controls (123 ng/mL), COPD patients (169 ng/mL), and various NSCLC subtypes (180-203 ng/mL).
- Elevated CgA was observed in 53% of limited-stage and 72% of extensive-stage SCLC patients.
- Higher CgA levels correlated with more advanced disease stages in SCLC.
- Four patients initially diagnosed with NSCLC showed elevated CgA, later revealed to have mixed SCLC/NSCLC.
Conclusions:
- Serum chromogranin A is a sensitive biomarker for small-cell lung carcinoma.
- CgA levels may reflect disease activity and stage in SCLC patients.
- The findings suggest CgA can aid in differentiating SCLC from other lung conditions and identifying mixed tumors.
